

**Supplementary Table 1:** Characteristics of all cancer patients and of the patients who received COVID-19 vaccination and ICI treatment

	<b>All patients (n=130) ICI + vac patients (n=89)</b>	
<b>General information:</b>		
Median age (range)	63 (21-88)	64 (31-88)
Women	51 (39%)	32 (36%)
Men	79 (61%)	57 (64%)
Median BMI (range)	26 (17-43)	26 (19-34)
Vaccinated patients	109 (84%)	89 (100%)
Vaccination not wanted	20 (15%)	n/a
No vaccination because of coronavirus infection	1 (0.8%)	n/a
<b>Tumor type:</b>		
Melanoma	113 (87%)	79 (89%)
Squamous cell carcinoma	8 (6%)	6 (7%)
Merkel cell carcinoma	4 (3%)	4 (4%)
Basal cell Carcinoma	1 (1%)	0 (0%)
Angiosarcoma	2 (1.5%)	0 (0%)
Lymphoma	2 (1.5%)	0 (0%)
<b>Anti-cancer therapy:</b>		
PD-1 antibody	79 (61%)	63 (71%)
PD-L1 antibody	6 (5%)	6 (7%)
CTLA4 + PD-1 antibody	24 (18%)	20 (22%)
CD-30 antibody	1 (1%)	n/a
Targeted therapy	6 (5%)	n/a
Chemotherapy	5 (4%)	n/a
Bispecific fusion protein	8 (6%)	n/a
Vaccination	1 (1%)	n/a
<b>Type of vaccine received by vaccinated patients:</b>		
BioNTech	94 (86%)	76 (86%)
Moderna	3 (3%)	2 (2%)
AstraZeneca	8 (7%)	8 (9%)
AstraZeneca + BioNTech	2 (2%)	2 (2%)
Johnson & Johnson	2 (2%)	1 (1%)
<b>Follow-up time after vaccination:</b>		
Median FU after first vaccination (range)	125 days (49-215)	125 days (69-215)
Median FU after second vaccination (range)	84 days (31-188)	84 days (34-188)

Abbreviations: BMI, body mass index. FU, follow-up. ICI, immune checkpoint inhibitors. n/a, not applicable. vac, vaccinated.